-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with relapsed or refractory multiple myeloma that are resistant to lenalidomide in the early treatment regimen require new effective therapies.
Patients with relapsed or refractory multiple myeloma that are resistant to lenalidomide in the early treatment regimen require new effective therapies.
These patients had received one or two treatments before, receiving pomalidomide 4 mg per day from day 1 to 21 and dexamethasone 40 mg per week ( 28- day cycle).
These patients had received one or two treatments before, receiving pomalidomide 4 mg per day from day 1 to 21 and dexamethasone 40 mg per week ( 28- day cycle).
According to the protocol, all patients ( N = 112 ) received lenalidomide in the most recent previous protocol ( 75.
According to the protocol, all patients ( N = 112 ) received lenalidomide in the most recent previous protocol ( 75.
In summary, these results indicate that for RRMM patients, even patients who have failed lenalidomide treatment , pomalidomide- based regimens should be used as second-line treatment as soon as possible, which has good safety and effectiveness, indicating that there is no need Change immunomodulator drugs.
In summary, these results indicate that for RRMM patients, even patients who have failed lenalidomide treatment , pomalidomide- based regimens should be used as second-line treatment as soon as possible, which has good safety and effectiveness, indicating that there is no need Change immunomodulator drugs.
Original source:
Original source:
David S Siegel, et al.
David S Siegel, et Al,.
Et Al,.
ncbi.
nlm.
nih.
gov/32376855/" target="_blank" rel="noopener">Pomalidomide, dexamethasone, and daratumumab in relapsed refractory Multiple myeloma After lenalidomide treatment Pomalidomide, dexamethasone, and daratumumab in relapsed refractory Multiple myeloma After lenalidomide treatment .
.
Leukemia 2020 On Dec;.
34 is (12 is ):3286-3297.
doi: 10.
1038/s41375-020-0813-1.
Leave a message here
